News about Market

Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment

After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.

Market | 14/11/2025 | By Darshana |  264

Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion

Merck & Co. is reportedly closing in on the acquisition of Cidara Therapeutics, a biotechnology company focused on long-acting antibody treatments for influenza. The deal is expected to value Cidara above its USD 3.3 billion market capitalisation.

Market | 14/11/2025 | By Darshana |  149

Natural Capsules Posts Stable Q2, but US Tariffs Slow HPMC Expansion

Natural Capsules, one of India’s leading capsule manufacturers, has announced its financial results for the quarter and half year ended September 30, 2025, reporting steady demand but acknowledging multiple external and operational challenges that have impacted growth.

Market | 14/11/2025 | By Dineshwori |  324

Lupin Receives EIR from US FDA for its Aurangabad (CSN) Facility

Lupin has received an Establishment Inspection Report (EIR) from the US FDA for its Aurangabad (CSN) facility, marking the successful closure of a product-specific Pre-Approval Inspection conducted between September 1 and September 5, 2025.

Market | 14/11/2025 | By Dineshwori |  227

JB Pharma Q2 FY26 Net Profit Rises 19 Percent to INR 208 Crore

JB Chemicals & Pharmaceuticals reported a net profit of INR 208 crore for the quarter ended September 30, 2025, marking a 19 percent year-on-year increase from INR 175 crore in the same period last year.

Market | 12/11/2025 | By Darshana |  179

GENFIT and EVerZom Partner to Advance Exosome-based Regenerative Technology in ACLF

Under the collaboration, GENFIT and EVerZom will combine expertise to advance EViv, an exosome-based regenerative therapy for ACLF, with GENFIT leading preclinical evaluation and EVerZom providing its bioproduction platform. GENFIT also holds an exclusive option to licence the programme following successful proof-of-concept results.

Market | 12/11/2025 | By Dineshwori |  224

Glenmark Secures China's Approval For RYALTRIS

Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.

Market | 11/11/2025 | By Dineshwori |  524

FDA Approves DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma

The US FDA has approved DARZALEX Faspro as the first treatment for adult patients with High-Risk Smoldering Multiple Myeloma (HR-SMM), marking a key milestone in addressing this early stage of the disease.

Market | 11/11/2025 | By Dineshwori |  189

Organon Announces Agreement to Divest its JADA System for up to USD 465 Million to Laborie

Organon has entered into a definitive agreement to divest its JADA System to Laborie for up to USD 465 million. The deal aims to leverage Laborie’s expertise in medical technology to expand the reach of JADA, enhancing access to postpartum hemorrhage treatment for mothers worldwide.

Market | 11/11/2025 | By Dineshwori |  344

Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India

Under this agreement, Emcure becomes the first Indian company to hold exclusive rights for the distribution and commercialisation of the drug, expanding access to Novo Nordisk’s innovative semaglutide therapy for people living with overweight and obesity in the country.

Market | 10/11/2025 | By Dineshwori |  771